This is a Los Angeles news story, published by CNBC, that relates primarily to Merck news.
For more Los Angeles news, you can click here:
more Los Angeles newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
respiratory syncytial virus. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Merck news, infant deaths news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
valuable new treatment optionCNBC
•
88% Informative
Merck said its experimental treatment showed positive results in a mid- to late-stage trial.
The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV .
Complications from the virus are the leading cause of hospitalization among newborns.
Merck presented the results at the medical conference IDWeek in Los Angeles .
VR Score
92
Informative language
96
Neutral language
31
Article tone
formal
Language
English
Language complexity
64
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links